Abstract
Transarterial chemoembollization (TACE) is a new and effective locoregional anticancer treatment option for advanced hepatocellular carcinoma patients. In a prospective study on 50 patients with hepatocellular cancer undergoing in total 77 TACE therapies, blood samples were taken before the start, as well as 3, 6 and 24 h after TACE therapy. Circulating nucleosomes were determined by ELISA and the patterns of nucleosome release in different T-stages were compared. Serum nucleosomes levels showed temporary decreases 3 and 6 h after TACE therapy which were subsequently followed by significant increases 24 h after TACE. Comparing the different groups of tumor stages, nucleosome levels were quite similar in the various groups with a tendency to higher values 24 h after TACE for patients with T3 disease. After a temporary decline, circulating nucleosomes increased 1 day after application of TACE therapy that may be relevant for the estimation of therapy efficacy.
The contributor “Dietrich Jüngst” is deceased
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Beachy SH, Repasky EA (2008) Using extracellular biomarkers for monitoring efficacy of therapeutics in cancer patients: an update. Cancer Immunol Immunother 57:759–775
Breedis C, Young G (1954) The blood supply of neoplasms in the liver. Am J Pathol 30:969–977
El-Serag HB, Marrero JA, Rudolph L et al (2008) Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134:1752–1763
Fabregat I (2009) Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 15:513–520
Holdenrieder S, Stieber P (2009) Clinical use of circulating nucleosomes. Crit Rev Clin Lab Sci 46:1–24
Holdenrieder S, Stieber P, Bodenmuller H et al (2001) Nucleosomes in serum as a marker for cell death. Clin Chem Lab Med 39:596–605
Holdenrieder S, Stieber P, von Pawel J et al (2006) Early and specific prediction of the therapeutic efficacy in lung cancer by nucleosomal DNA and cytokeratin 19 fragments. Ann NY Acad Sci 1075:244–257
Jing Z, Nan K-J, Hu M-L (2005) Cell proliferation, apoptosis and the related regulators p27, p53 expression in hepatocellular carcinoma. World J Gastroenterol 11:1910–1916
Kremer A, Wilkowski R, Holdenrieder S et al (2005) Nucleosomes in pancreatic cancer patients during radiochemotherapy. Tumour Biol 26:44–49
Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37:429–442
Meyn RE, Stephens LC, Ang KK et al (1993) Heterogeneity in the development of apoptosis in irradiated murin tumors of different histologies. Int J Radiat Biol 64:583–591
Parkin DM, Bray F, Ferlay J et al (2001) Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 94:153–156
Acknowledgment
We are very grateful for the committed support of Prof. Jüngst who died recently. The work is part of the doctoral thesis of Nikolaus Kohles.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer Science+Business Media B.V.
About this paper
Cite this paper
Kohles, N., Nagel, D., Jüngst, D., Durner, J., Stieber, P., Holdenrieder, S. (2010). The Course of Circulating Nucleosomes in Liver Cancer Patients Undergoing Transarterial Chemoembolization Therapy. In: Gahan, P. (eds) Circulating Nucleic Acids in Plasma and Serum. Springer, Dordrecht. https://doi.org/10.1007/978-90-481-9382-0_10
Download citation
DOI: https://doi.org/10.1007/978-90-481-9382-0_10
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-90-481-9381-3
Online ISBN: 978-90-481-9382-0
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)